{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"pt-141-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"pt-141-neuropathy","title":"PT-141 for Neuropathy: Evidence-Graded Review","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:08.368Z","body_excerpt":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\n\n## Why PT-141 might help you\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \n\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\n\n## How these fit together\n\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no neuropathy cohorts (human tier, n>1000 across RECONNECT studies). Diabetic ED trials noted benefits in men with diabetes-related ED, yet measured sexual function scores only (human tier). No rat or animal studies directly test PT-141 on neuropathic pain models or nerve regeneration (preclinical tier: zero relevant studies located).\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin agonist acting centrally on MC3/MC4 receptors to drive arousal independent of vascular pathways. Publications note its utility in PDE5 non-responders but explicitly limit claims to sexual dysfunction endpoints. No peer-reviewed statements link the compound to nerve repair or neuropathy resolution (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports center on erectile effects and libido. Users with presumed diabetic or age-related issues describe stronger spontaneous erections and mental arousal after 1–2 mg doses, sometimes combined with PDE5 inhibitors. Nausea and flushing are commonly noted side effects. No posts report changes in neuropathic pain, numbness, or nerve function (anecdotal tier). One thread contrasts PT-141 with Melanotan-2, noting the latter's limited animal data on nerve regeneration while stating PT-141 lacks such observations.\n\n## What people say on X\n\nNo matching posts discuss PT-141 in the context of neuropathy or neuropathic symptoms (anecdotal tier: zero relevant reports).\n\n## What we do not know\n\nHuman data on PT-141 for any neuropathy endpoint is absent. Preclinical work on melanocortin agonists and nerve injury is limited to unrelated compounds. Long-term effects on nerve health remain unstudied. Dose-response relationships for non-sexual outcomes are unknown.\n\n## Safety and limits\n\nCommon effects in human trials include nausea (up to 40% of participants), flushing, and headache. Serious adverse events were rare in HSDD studies. PT-141 is not approved or studied for neuropathy; any use falls outside labeled indications. Evidence grade remains mechanistic or anecdotal for this condition.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"No human trials examine PT-141 for neuropathy itself.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the queried condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Phase 3 bremelanotide trials demonstrated increased desire scores versus placebo in HSDD.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Provides human efficacy data but not for neuropathy.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"Early MT-II study included men with peripheral neuropathic injury but measured only erectile response.","tier":"mechanistic","weight":0.3,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Shows incidental inclusion of neuropathy patients without neuropathy outcome data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Reddit users report stronger erections and arousal but no changes in neuropathic pain or nerve function.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Documents user experience separate from clinical data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","summary":"Reviews PT-141 studies limited to ED endpoints; no neuropathy data.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","summary":"Small crossover study of related compound including neuropathy patients but only ED outcomes.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","summary":"Phase 3 HSDD data; no neuropathy cohorts.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","summary":"User reports focus on sexual effects; no neuropathy mentions.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"edfce5464843768c4c91d049cb988df949c2f5d41ff6e4403bf666ddec5f908b"}],"anecdotal_sources":[{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1clpo4k/taken_pt141_twice_now_and_i_am_happily_amazed/","title":"Taken PT-141 twice now and I am happily amazed","quote":"This stuff works for me!!! Not only did I feel 19 again and gave me the best hard-ons I've ever had...","summary":"User reports focus on sexual effects; no neuropathy mentions.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"edfce5464843768c4c91d049cb988df949c2f5d41ff6e4403bf666ddec5f908b"}],"scientific_sources":[{"id":"s1","type":"review","url":"https://wjmh.org/DOIx.php?id=10.5534/wjmh.200007","title":"Novel Emerging Therapies for Erectile Dysfunction","quote":"Bremelanotide is a carboxylated metabolite of MT-II, and was formerly known as PT-141.","summary":"Reviews PT-141 studies limited to ED endpoints; no neuropathy data.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"47223ca5edb11d9aeaa822121caa428c9337418f0c77f8b74196368ab8e80523"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18206919/","title":"Salvage of sildenafil failures with bremelanotide","quote":"Organic risk factors for ED that were present in the 10 subjects included ... peripheral neuropathic injury ...","summary":"Small crossover study of related compound including neuropathy patients but only ED outcomes.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"8b78d7eb02167b83122c9cc2effc05fd2f5100d0f3b8bfb3bda5be76eef39abb"},{"id":"s3","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder.","summary":"Phase 3 HSDD data; no neuropathy cohorts.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"659ba8098942df67c20d8a368ed5f5c2a7fa926fc9899544d09157a970fc14b9"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"pt-141-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":4,"anecdotal":1,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}